Integrated Nanotherapeutics Inc.: federal grants and contributions: 12 agreements; $1.6M value; 3 departments; 6 programs.
Assay record ASY-CA-1GAEIPH0GI · Cite as: Assay Systems, “Integrated Nanotherapeutics Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/integrated-nanotherapeutics-inc/
Evaluation of a tolerogenic LNP (lipid nanoparticle) formulation to treat type 1 diabetes in non-obese diabetic (NOD) mice, an established mouse model of type 1 diabetes.
Development of INT-101 formulation for human dosing and prevention of diabetes
This project aims to develop effective immunomodulatory formulations to induce immune tolerance as a therapeutic strategy for autoimmune and inflammatory diseases.
This project aims to develop effective immunomodulatory formulations to induce immune tolerance as a therapeutic strategy for autoimmune and inflammatory diseases.
Develop and market novel therapies for the treatment of diabetes
Development of lipid nanoparticles (LNP) encasing mRNA for vaccines.
ICAP 2022 – International Co-Innovation Action Plan
Development of immunomodulatory formulations for inflammatory diseases
The purpose of the Canadian International Innovation Program (CIIP) contribution agreement is to support Canadian SMEs identify international partners in CIIP target countries for industrial research and development collaboration that has good potential for commercialization.
The purpose of this CanExport Innovation (CXI) grant agreement is to support organizations and to build on targeted relationships between Canadian companies/researchers and key organizations in other countries to allow them to proceed with formal discussions to initiate collaboration(s) on future international R&D initiatives that could lead to commercialization of Canadian technologies.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.